Spring House, PA, United States of America

Shun Xin Wang Lin

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Janssen Biotech, Inc.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shun Xin Wang Lin. Retrieved from https://idiyas.com/inventor/shun-xin-wang-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shun Xin Wang Lin: Innovator in Cancer Treatment

Introduction

Shun Xin Wang Lin is a notable inventor based in Spring House, PA (US). He has made significant contributions to the field of cancer treatment, particularly in the area of multiple myeloma. His innovative work has led to the development of methods that could potentially improve patient outcomes.

Latest Patents

Shun Xin Wang Lin holds 1 patent for his groundbreaking work titled "Methods for treating multiple myeloma." This patent describes methods of treating cancers using a BCMAxCD3 bispecific antibody, showcasing his commitment to advancing medical science.

Career Highlights

He is currently employed at Janssen Biotech, Inc., where he continues to focus on innovative cancer therapies. His role at the company allows him to collaborate with other experts in the field and contribute to the development of new treatment options.

Collaborations

Some of his coworkers include Suzette Girgis and Homer Adams, who work alongside him in the pursuit of innovative cancer treatments. Their combined expertise enhances the research and development efforts at Janssen Biotech, Inc.

Conclusion

Shun Xin Wang Lin's contributions to cancer treatment through his patent and work at Janssen Biotech, Inc. highlight his dedication to improving healthcare. His innovative methods for treating multiple myeloma represent a significant advancement in the fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…